Biomedx GmbH, of Heidelberg, Germany, said it entered a collaboration agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to establish a research group focusing on the identification of therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD).